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Studies in community-acquired pneumonia (CAP) have compared grepafloxacin, 600 mg 0.d. for 7-10 days, with 
amoxycillin, 500 mg t.d.s., cefaclor, 500 mg t.d.s, or clarithromycin, 250 mg b.d. Grepafloxacin appeared to be clinically 
as effective as the comparators. In CAP caused by Haemophilus influenzae, grepafloxacin was significantly superior to 
amoxycillin (p=0.005) and cefaclor (p=0.003) and equivalent to clarithromycin in eradicating the infecting organism. 
Bacterial eradication with grepafloxacin in CAP caused by Moraxella cafarrhalis or Streptococcus pneumoniae was 
effective and equivalent to the comparator antibiotic. In an open study, grepafloxacin was also effective in treating 
atypical pneumonia caused by Mycoplasma pneumoniae and Legionella pneumophila. 
In acute bacterial exacerbations of chronic bronchitis (ABECB), studies have found once-daily treatment with 
grepafloxacin, 400 mg or 600 mg for 7-10 days, to be equivalent to arnoxycillin, 500 mg t.d.s., or ciprofloxacin, 500 mg 
b.d. In patients with documented infections, bacteriologic eradication with grepafloxacin, 400 mg or 600 mg o.d., was 
superior to amoxycillin, 500 mg t.d.s. 
Results from clinical trials so far indicate that grepafloxacin has a broad spectrum of activity covering all important 
community-acquired respiratory pathogens, and may be suitable for the empirical treatment of respiratory infection. 
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The management of lower respiratory tract infection 
(LRTI) poses a considerable clinical problem. In the 
USA there are around 4 x lo6 cases of adult com- 
munity-acquired pneumonia (CAP) each year, over 
600000 of which are hospitalized [1,2]. The cost of 
treating these hospitalized patients has been estimated 
at approximately US $4 billion a year [2-41. Data from 
the UK have shown that around 16.3 x lo6 episodes of 
community-acquired LRTI are reported annually, at an 
approximate cost of L1364 million ($2.25 bilLon) [ 5 ] .  
While only 1.4% of these cases are hospitalized, they 
account for 62% of this cost, even though 13% of these 
hospitalized patients are discharged within 1 day. Thus, 
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hospitahzation represents an extremely costly event in 
the management of LRTI. 
Several recent studies have investigated the efficacy 
and tolerability of outpatient treatment with the fluoro- 
quinolone grepafloxacin in CAP and acute bacterial 
exacerbations of chronic bronchitis (ABECB), both in 
open trials and against comparator antibiotics. This 
paper will consider the results of these trials. 
CURRENT MANAGEMENT STRATEGIES 
The management of LRTI represents a challenge to 
clinicians. Treatment is often empirical, particularly in 
the outpatient setting where most infections occur, and 
since the causative pathogen is rarely identified, LRTI 
is associated with a wide range of respiratory pathogens, 
with shifting patterns of antibiotic susceptibility that 
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vary between different cities, hospitals and clinics. 
Another complicating factor is clinicians’ uncertainties 
as to the need to hospitalize such patients, a decision 
hampered by the lack of firm guidelines on assessing 
the severity of disease. A recent study by Fine and 
colleagues has proposed a prediction rule based on 
various risk factors to facilitate the identification of 
those patients at  low risk of death and other adverse 
outcomes 161. 
The range of patient outcomes in LRTI is huge 
and the severity of disease can vary widely, from acute 
tracheobronchitis in an otherwise healthy person in 
whom death is unlikely, to pneumonia in a patient with 
underlying severe chronic lung disease or cardio- 
respiratory disease in whom death is more probable. A 
part of the decision of which patients can be managed 
in the community depends on the therapeutic agents 
available to allow home treatment. 
CLINICAL STUDIES OF GREPAFLOXACIN 
Clinical studies on grepafloxacin have been conducted 
in the USA, the UK and Eire. The numbers of subjects 
entered in these studies were statistically calculated to 
show clinical equivalence. An additional design feature 
(often used) may have affected the study results. In 
the CAP studies, any patient who had an organism 
recovered that was resistant to any of the study drugs 
was excluded. 
Community-acquired pneumonia 
In a number of clinical studies in CAP (and ACEB) 
(7-121, completed by 1996, 881 patients who received 
grepafloxacin and 625 who received comparator anti- 
biotics were evaluated. Four studies in patients with 
CAP have used grepafloxacin, 600 mg o.d., for 7- 
10 days. The comparator antibiotic in three studies was 
amoxycillin, 500 mg t.d.s., cefaclor, 500 mg t.d.s., or 
clarithromycin, 250 mg b.d., and the fourth was an 
open study. 
Clinical response 
Overall clinical results obtained with grepafloxacin at 
3-5 days post-treatment in the clinically evaluable 
population, which included patients from whom no 
pathogen was isolated, were similar throughout the 
open and comparative studies and equivalent to the 
comparators (Figure 1). In clinically evaluable patients 
from whom a susceptible pathogen was isolated, clinical 
success rates were comparable in all studies. 
Clinical success rates at  28-42 days post-treatment 
in the clinically evaluable population were 76 and 77% 
in the study of grepafloxacin versus amoxycillin (Figure 
2), and 73% and 80%, respectively, in the study of 
grepafloxacin versus cefaclor. The rates obtained with 
grepafloxacin and clarithromycin were slightly higher 
(83% and 89%, respectively). In the open study, 89% 
of patients still felt well at this time. Considering 
those patients from whom a pathogen was isolated 
pretreatment, the clinical success rate was 79% for 
grepafloxacin compared to 63% for amoxycillin [12] 
(79% versus 63%; 95% CI= -5.296, 38.1%; Figure 3). 
In the open study, 93% of these patients were success- 
fully treated. 
Clinical response in atypical pneumonia was also 
assessed in those patients enrolled in the open study 
who had serologic evidence of Mycoplarma pneumoniae 
or Legionella pneumophila infection. The clinical success 
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Figure 1 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 3-5 days post-treatment in the 
clinically cvaluable population. 
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Figure 2 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 28-42 days post-treatment in the 
clinically evaluable population. 
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Figure 3 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 28-42 days post-treatment in the 
microbiologically and clinically evaluable population. 
rates with grepafloxacin at 3-5 days and 28-42 days 
were 98% (n=59) and 88% (n=59) for Mycoplasma 
pneumoniae, and 93% (n=14) and 86% ( ~ ~ 1 4 )  for L. 
pneumophila, respectively. 
Microbiological response 
When microbiological success was assessed at 3-5 days 
post-treatment, Streptococcus pneumoniae was eradicated 
in 88% of infections ( ~ ~ 1 4 4 )  treated with grepafloxacin, 
93% (n=15) treated with amoxycillin, 84% (n=37) 
treated with cefaclor and 91% (n=46) treated with 
clarithromycin. These results were not statistically 
different. Elimination of Haemophilus injuenzae with 
grepafloxacin was superior to that obtained with 
amoxycillin, cefaclor and clarithromycin (Figure 4). 
Moraxella catarrhalis is another important respiratory 
pathogen, with around 80% of strains exhibiting 
p-lactamase activity. This activity is the most likely 
explanation for the eradication rate of 67% obtained 
with amoxycillin, compared with the rate of 85% 
obtained with grepafloxacin (~ '0 .5 ;  Figure 5). No 
significant differences in microbiological success rate 
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Figure 4 Eradication of Huemophilus injireniae with grepafloxacin versus Comparator drugs at 3-5 days post-treatment in 
the microbiological intent-to-treat population. 
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Figure 5 Eradication of Moraxella catavrhalis with grepafloxacin versus comparator drugs at  3-5 days post-treatment in the 
microbiological intent-to-treat population. 
were seen between grepafloxacin and cefaclor (86%) or 
clarithromycin (96%). 
Susceptibility patterns 
The activities of grepafloxacin, amoxycdin, clari- 
thromycin and cefaclor against common respiratory 
pathogens are shown in Table 1. 
Streptococcus pneumoniae infection 
Of the 881 patients receiving grepafloxacin in these 
CAP studies, 127 had documented infections with 
Streptococcus pneurnoniae. Microbiological cure was 
achieved in 121 (95%) of these infections at 3-5 days 
post-treatment. These studies were conducted at a 
time when penicillin resistance in S. pneumoniae was 
relatively uncommon in the USA and the UK. Three 
of these 127 strains were penicillin-resistant, all of 
which were eradicated by grepafloxacin, as were 18 
out of 19 (94%) of the penicdlin-intermediate isolates. 
In all, 80 (95%) of the 84 Streptococcus pnenrnoniae 
infections treated with a comparator antibiotic were 
resolved. 
Summary 
In cases of CAP due to H .  influenzae, the microbio- 
logical success rate achieved with grepafloxacin was 
statistically significantly superior to that obtained with 
amoxycillin and cefaclor. Similarly, in CAP caused 
by iMoraxella catarrhah, bacterial eradication with 
grepafloxacin was superior to that with amoxycillin, 
although the number of organisms in the amoxycillin 
group was small (n=6).  Grepafloxacin was also 
found to be effective and equivalent to amoxycillin, 
cefaclor and clarithromycin in the eradication of 
Streptococcus pneumoniae. The open study also reported 
grepafloxacin to be effective in treating atypical 
pneumonias caused by Mycoplasma pneumoniae and L. 
pneumophila. 
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Table 1 Activity of grepafloxacin and comparator antibiotics against common respiratory pathogens 
MIC90 (mg/L) 
Organism Grepdoxacin Amoxycdhn Clarithromycin Cefaclor Ciprofloxacin 
Sfrepfococcus pneumoniae [13] 
Haemophilus inzuenzae [13] 
0-Lactarnase negative 
0-Lactamase positive 
Moraxella cafarrhalis [13] 
Staphylocouus auwu (141 
Chlamydia pneumoniae [15] 
Mycoplacma pneumoniae [15] 
Legionella pneumophila [15] 
0.25 
0.008 
0.008 
0.015 
0.12 
0.12 
0.5 
0.015 
0.015 
1 
32 
2 
N/D 
N/D 
N/D 
N/D 
0.06 
8 
8 
0.03 
N/D 
0.06 
0.015 
0.03 
0.5 
8 
8 
0.5 
N/D 
N/D 
N/D 
N/D 
2 
0.015 
0.015 
0.03 
1 
N/D 
N/D 
N/D 
N/D=not done. 
Acute bacterial exacerbations of chronic bronchitis 
The characteristics of patients with ABECB can be 
quite different to those of patients with CAP. Many 
patients with CAP will have no pre-existing chronic 
lung disease, whereas all sufferers of ABECB have pre- 
existing chronic disease and lung damage. 
Two major studies have been performed in 
ABECB, with 849 patients treated with grepafloxacin 
and 431 with comparator antibiotics. The first study, 
conducted in the UK, compared treatment with 
grepafloxacin, 400 mg or 600 mg o.d., or amoxycillin, 
500mg t.d.s., for 7 or 10 days. The second study in 
the USA compared the same doses of grepafloxacin 
with ciprofloxacin, 500 mg b.d., for 10 days. Patient 
numbers w.d demographic characteristics were com- 
parable between the studies. 
Clinical response 
The clinical cure rates at 3-5 days post-treatment in the 
clinically evaluable population were 90% (1 86/207) and 
94% (194/207) with grepafloxacin, 400 mg and 600 
mg, respectively, compared with 92% (187/203) with 
amoxycillin. At 14-28 days post-treatment, clinical 
success rates were 82% (165/202) for grepafloxacin, 
400 mg, 85% (175/206) for grepafloxacin, 600 mg, 
and 85% (172/203) for amoxycillin (no statistical 
difference). Thus, clinical success was sustained for a 
reasonable period of time. 
In the US study, at 14-28 days’ follow-up, the 
clinical success rate was 87% (124/143) for grepa- 
floxacin, 400 mg, 81% (1221151) for grepafloxacin, 
600 mg, and 80% (123/154) for ciprofloxacin. These 
differences were not significant. 
Microbiological response 
In the UK study, microbiological success rates in 
the microbiologically and clinically evaluable popula- 
tion at 3-5 days post-treatment were comparable 
for grepafloxacin, 400 mg, and amoxycillin against 
Streptococcus pneumoniae infection (95% versus 98%). 
Grepafloxacin achieved a hgher microbiological success 
rate against H. inzuenzae compared with amoxycillin 
(99% versus 89%), but this difference was not signi- 
ficant. Similarly, against Moraxella catarrhah infections, 
grepafloxacin successfully treated 100% of infections 
compared with 90% eradication with amoxycillin (not 
significant). 
Microbiological success rates in this population 
in the US study against Streptococcus pneumoniae at 3-5 
days post-treatment were 88% (7/8) for grepafloxacin, 
600 mg, compared with 40% for ciprofloxacin (2/5). 
This small number of isolates virtually precludes find- 
ing statistical differences. Both drugs demonstrated 
equivalent microbiological eradication rates against 
infections caused by H .  injuenzae (100%) and Mora- 
xella catarrhalis (95%) 
For the microbiological intent-to-treat population, 
the cumulative results achieved in both studies of 
ABECB in the microbiological eradication of Strepto- 
coccus pneumoniae infection at 3-5 days post-treatment 
were 84% (48/57) and 94% (49/52) with grepafloxacin 
400 mg and 600 mg, respectively, compared with 
96% (43145) with amoxycillin and 50% (316) with 
ciprofloxacin. Similar results were obtained in the 
microbiologically and clinically evaluable populations 
at 3-5 days post-treatment. 
Overall clinical outcome 
Analysis of the clinical results obtained in the 849 
patients treated with grepafloxacin and the 431 treated 
with a comparator antibiotic showed the clinical 
equivalence of grepafloxacin, 400 mg and 600 mg. 
Overall clinical efficacy at 14-28 days post-treatment 
demonstrated the equivalence of once-daily dosing 
with grepafloxacin, 400 mg or 600 mg, and amoxycillin, 
500 mg t.d.s., or ciprofloxacin, 500 mg b.d. in patients 
with documented infections, bacteriologic eradication 
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Table 2 Most common adverse events in multiple-dose 
studies” 
Grepafloxacin, Grepafloxacm, All control$ 
Adverse 400 mg 600 mg (n=1579) 
event (w=1069) (x) (n=1406) @) (“A) 
Nausea 11.8 
Unpleasant taste 0.C 
Headache 7.5 
Dizziness 5.0 
Vaginitis ‘’ 5.1 
Vomiting 2.2 
Diarrhpea 3.9 
Rhinitis 3.1 
15.4 
16.8 
8.1 
1 .4 
6.3 
7.6 
i . 2  
5.9 
8.1 
1.6 
8.9 
5.4 
2.9 
3.7 
4.4 
3.8 
”Adverse events reported with an incidence 2 5 % .  ”Incidence is 
the percentage of females in the group that experienced this 
adverse event. 
with grepafloxacin, 400 mg or 600 mg o.d., was 
superior to amoxycillin, 500 mg t.d.s [12]. 
The most common adverse effects (those occurring 
with an incidence 1 5 % )  in multiple-dose studies 
are shown in Table 2. Although the safety data for 
ciprofloxacin are included in the ‘all controls’ group, 
these data were similar to those seen with grepafloxacin. 
Reports of taste perversion increased slightly with 
increasing grepafloxacin dose, as did vomiting. In 
general, all side effects were rated as mild-to-moderate. 
The rate of treatment discontinuation due to 
adverse events was low in these multiple-dose studies. 
Nausea and vomiting at the grepafloxacin dose of 
600 mg accounted for most of the problems seen 
with this drug (Table 3). Dizziness, headache and 
other central nervous system (CNS) effects were not 
significant problems, which is probably accounted for 
by the fact that grepafloxacin has limited penetration of 
the blood-brain barrier. The low CNS effect may be 
an advantage over some other quinolones. 
Table 3 Discontinuations due to adverse events in 
multiple-dose studies 
Grepafloxacin, Grepafloxacin, 
Adverse 400 mg 600 mg AU controls 
event (rz=1069) (YO) (n=1406) (%) (n=1579) (%) 
Nausea 9 (0.8) 37 (2.6) 14 (0.9) 
Vomiting 6 (0.6) 20 (1.4) 11 (0.7) 
Dizziness 5 (0.5) 9 (0.6) 3 (0.2) 
Abdominal pain 3 (0.3) 4 (0.3) 2 (0.1) 
Unpleasant taste 3 (0.3) 14 (1.0) 0 (0.0) 
Rarh 2 (0.2) 9 (0.6) 2 (0.1) 
Headache 3 (0.3) 9 (0.6) 6 (0.4) 
Cardiovascular system 
Prolongation of the QTc  interval has now been seen 
with a number of antibiotics in the niacrolide and 
quinolone groups. A recent study by Tschida et a1 [16], 
demonstrated that erythromycin prolonged the Q T c  
interval by 31 msec. Grepafloxacin has been studied 
in 48 elderly male and female subjects, and a small 
increase in the QTc of less than 2 msec was observed. 
Grepafloxacin is contra-indicated in patients with 
known QTc  prolongation, or in those being treated 
concomitantly with medications known to produce an 
increase in the QTc  interval and consideration must 
be given to this when administering grepafloxacin. 
However, careful analysis of the clinical trial results 
showed that no events of any clinical significance could 
be attributed to the prolongation of QTc  interval. In 
addition, there was no evidence of arrhythmias induced 
by grepafloxacin, despite a number of these patients 
receiving concomitant pro-arrhythmic drugs. 
Photosensitivity 
Skin photosensitivity is a known side effect of quino- 
lone therapy, with a severity that varies between 
different agents. Single-dose studies with grepafloxacin 
have reported no cases ofphotosensitivity. In multiple- 
dose studies, the incidence of photosensitivity reported 
with grepafloxacin, 400 mg and 600 mg o.d., was 0.7% 
and 2%, respectively. Three photosensitivity reactions 
have been described as severe (0.1%), and three patients 
have been withdrawn from clinical trials with grepa- 
floxacin because of photosensitivity reactions (one mild, 
one moderate and one severe). A comparative study of 
grepafloxacin and ciprofloxacin has shown an equi- 
valent incidence of photosensitivity with these agents. 
Photosensitivity is generally reported 1-5 days post- 
treatment, and patients in clinical trials of grepafloxacin 
have not been subjected to special restrictions regarding 
sunlight exposure. 
Overall safety 
Overall, the potential for grepafloxacin to evoke 
photosensitivity reactions is low, as is the incidence of 
arthropathy and photocarcinogenicity. Grepafloxacin 
has also demonstrated a low potential for non-steroidal 
anti-inflammatory drug potentiation of quinolone 
inhibition of GABA-receptor binding. CNS pene- 
tration by grepafloxacin is poor and, thus, a low 
incidence of CNS side effects has been reported in 
clinical studies. 
CONCLUSIONS 
Clinical studies in CAP have shown that once-daily 
treatment with grepafloxacin, 600 mg for 10 days, SS
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is clinically equivalent to both clarithromycin, 250 mg 
b.d., and cefaclor, 500 mg t.d.s. for 10 days, and 
superior to amoxycillin, 500 mg t.d.s. for 10 days, in 
patients with documented bacteriologic infections. 
Grepafloxacin was effective in the treatment of both 
typical and atypical pneumonias. 
In ABECB, once-daily treatment with grepa- 
floxacin, 400 mg or 600 mg (for 7 or 10 days), was 
equivalent to amoxycillin, 500 mg t.d.s., and cipro- 
floxacin, 500 mg b.d. (for 7 or 10 days). In patients with 
documented infection, bacteriologic eradication with 
both grepafloxacin doses was superior to amoxycillin, 
500 mg t.d.s for 7 or 10 days. 
Grepafloxacin has a broad spectrum of activity 
covering all important respiratory pathogens, and 
so may be suitable for the empirical treatment of 
community-acquired respiratory infections. In practice, 
empirical therapy of these infections is likely to 
continue, rather than clinicians first attempting to 
identifj. the causative organisms and ascertain whether 
they are even infectious in nature (as many cases of 
ABECB are not). Thus, it is important that, when an 
antibiotic is used, it is effective. Grepafloxacin is well 
tolerated and has an acceptable safety profile. Clinical 
trials have shown that adverse events are mild and not 
associated with a high incidence of treatment failure or 
withdrawal. In addition, the once-daily dosing regimen 
of grepafloxacin offers potential advantages in terms of 
patient compliance. 
The findings of clinical trials so far indicate 
that grepafloxacin, 400 mg or 600 mg o.d., offers an 
effective, new treatment option in the community 
management of respiratory infection, and may offer 
the potential for considerable economic savings. In 
light of increasing bacterial resistance to penicillins 
and macrolides, the extended Gram-positive activity of 
grepafloxacin, which covers p-lactam and macrolide 
resistance, should offer important clinical benefits. 
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